Literature DB >> 23764004

SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.

Linfeng Chen1, Stefano Monti, Przemyslaw Juszczynski, Jing Ouyang, Bjoern Chapuy, Donna Neuberg, John G Doench, Agata M Bogusz, Thomas M Habermann, Ahmet Dogan, Thomas E Witzig, Jeffery L Kutok, Scott J Rodig, Todd Golub, Margaret A Shipp.   

Abstract

B cell receptor (BCR) signaling pathway components represent promising treatment targets in diffuse large B cell lymphoma (DLBCL) and additional B cell tumors. BCR signaling activates spleen tyrosine kinase (SYK) and downstream pathways including PI3K/AKT and NF-κB. In previous studies, chemical SYK blockade selectively decreased BCR signaling and induced apoptosis of BCR-dependent DLBCLs. Herein, we characterize distinct SYK/PI3K-dependent survival pathways in DLBCLs with high or low baseline NF-κB activity including selective repression of the pro-apoptotic HRK protein in NF-κB-low tumors. We also define SYK/PI3K-dependent cholesterol biosynthesis as a feed-forward mechanism of maintaining the integrity of BCRs in lipid rafts in DLBCLs with low or high NF-κB. In addition, SYK amplification and PTEN deletion are identified as selective genetic alterations in primary "BCR"-type DLBCLs.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23764004      PMCID: PMC3700321          DOI: 10.1016/j.ccr.2013.05.002

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  49 in total

Review 1.  Location is everything: lipid rafts and immune cell signaling.

Authors:  Michelle Dykstra; Anu Cherukuri; Hae Won Sohn; Shiang-Jong Tzeng; Susan K Pierce
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

2.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma.

Authors:  George Wright; Bruce Tan; Andreas Rosenwald; Elaine H Hurt; Adrian Wiestner; Louis M Staudt
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-04       Impact factor: 11.205

3.  Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer.

Authors:  Manfred Kraus; Marat B Alimzhanov; Nikolaus Rajewsky; Klaus Rajewsky
Journal:  Cell       Date:  2004-06-11       Impact factor: 41.582

4.  In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death.

Authors:  K P Lam; R Kühn; K Rajewsky
Journal:  Cell       Date:  1997-09-19       Impact factor: 41.582

5.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

6.  Aberrant B cell development and immune response in mice with a compromised BCR complex.

Authors:  R M Torres; H Flaswinkel; M Reth; K Rajewsky
Journal:  Science       Date:  1996-06-21       Impact factor: 47.728

7.  Specific and rapid induction of the proapoptotic protein Hrk after growth factor withdrawal in hematopoietic progenitor cells.

Authors:  C Sanz; A Benito; N Inohara; D Ekhterae; G Nunez; J L Fernandez-Luna
Journal:  Blood       Date:  2000-05-01       Impact factor: 22.113

8.  The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-kappaB that blocks TNFalpha-induced apoptosis.

Authors:  W X Zong; L C Edelstein; C Chen; J Bash; C Gélinas
Journal:  Genes Dev       Date:  1999-02-15       Impact factor: 11.361

9.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Wing C Chan; Joseph M Connors; Elias Campo; Richard I Fisher; Randy D Gascoyne; H Konrad Muller-Hermelink; Erlend B Smeland; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Liming Yang; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; John Powell; Patricia L Duffey; Dan L Longo; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Emilio Montserrat; Armando López-Guillermo; Thomas M Grogan; Thomas P Miller; Michel LeBlanc; German Ott; Stein Kvaloy; Jan Delabie; Harald Holte; Peter Krajci; Trond Stokke; Louis M Staudt
Journal:  N Engl J Med       Date:  2002-06-20       Impact factor: 91.245

10.  Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells.

Authors:  R E Davis; K D Brown; U Siebenlist; L M Staudt
Journal:  J Exp Med       Date:  2001-12-17       Impact factor: 14.307

View more
  67 in total

1.  Targeting Bruton's tyrosine kinase signaling as an emerging therapeutic agent of B-cell malignancies.

Authors:  Bing Xia; Fulian Qu; Tian Yuan; Yizhuo Zhang
Journal:  Oncol Lett       Date:  2015-10-13       Impact factor: 2.967

Review 2.  Rationale for targeting the pre-B-cell receptor signaling pathway in acute lymphoblastic leukemia.

Authors:  Markus Müschen
Journal:  Blood       Date:  2015-04-15       Impact factor: 22.113

Review 3.  Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.

Authors:  Rosalba Camicia; Hans C Winkler; Paul O Hassa
Journal:  Mol Cancer       Date:  2015-12-11       Impact factor: 27.401

4.  Activation of peroxisome proliferator-activated receptor γ ameliorates monocrotaline-induced pulmonary arterial hypertension in rats.

Authors:  Xinming Xie; Guizuo Wang; Dexin Zhang; Yonghong Zhang; Yanting Zhu; Fangwei Li; Shaojun Li; Manxiang Li
Journal:  Biomed Rep       Date:  2015-05-21

5.  FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells.

Authors:  Martine van Keimpema; Leonie J Grüneberg; Michal Mokry; Ruben van Boxtel; Jan Koster; Paul J Coffer; Steven T Pals; Marcel Spaargaren
Journal:  Blood       Date:  2014-09-29       Impact factor: 22.113

Review 6.  Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.

Authors:  Ryan M Young; James D Phelan; Wyndham H Wilson; Louis M Staudt
Journal:  Immunol Rev       Date:  2019-09       Impact factor: 12.988

Review 7.  NF-κB signaling pathway and its potential as a target for therapy in lymphoid neoplasms.

Authors:  Li Yu; Ling Li; L Jeffrey Medeiros; Ken H Young
Journal:  Blood Rev       Date:  2016-10-13       Impact factor: 8.250

8.  B-cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies.

Authors:  K Bojarczuk; M Siernicka; M Dwojak; M Bobrowicz; B Pyrzynska; P Gaj; M Karp; K Giannopoulos; D G Efremov; C Fauriat; J Golab; M Winiarska
Journal:  Leukemia       Date:  2014-01-10       Impact factor: 11.528

Review 9.  Advances in targeted therapy for malignant lymphoma.

Authors:  Li Wang; Wei Qin; Yu-Jia Huo; Xiao Li; Qing Shi; John E J Rasko; Anne Janin; Wei-Li Zhao
Journal:  Signal Transduct Target Ther       Date:  2020-03-06

10.  FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.

Authors:  T Sewastianik; M Szydlowski; E Jablonska; E Bialopiotrowicz; P Kiliszek; P Gorniak; A Polak; M Prochorec-Sobieszek; A Szumera-Cieckiewicz; T S Kaminski; S Markowicz; E Nowak; M A Grygorowicz; K Warzocha; P Juszczynski
Journal:  Oncogene       Date:  2016-05-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.